195 related articles for article (PubMed ID: 22313038)
1. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4.
Ohbuchi M; Noguchi K; Kawamura A; Usui T
Xenobiotica; 2012 Jul; 42(7):633-40. PubMed ID: 22313038
[TBL] [Abstract][Full Text] [Related]
2. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
[TBL] [Abstract][Full Text] [Related]
3. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
5. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.
Furuta T; Iwaki T; Umemura K
Br J Clin Pharmacol; 2010 Sep; 70(3):383-92. PubMed ID: 20716239
[TBL] [Abstract][Full Text] [Related]
6. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
[TBL] [Abstract][Full Text] [Related]
7. In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors.
Moody DE; Liu F; Fang WB
J Anal Toxicol; 2013 Oct; 37(8):476-85. PubMed ID: 23857299
[TBL] [Abstract][Full Text] [Related]
8. Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition.
Zhang H; Ragueneau-Majlessi I; Levy RH
Drug Metab Lett; 2009 Dec; 3(4):287-9. PubMed ID: 19995331
[TBL] [Abstract][Full Text] [Related]
9. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
10. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.
Hagihara K; Nishiya Y; Kurihara A; Kazui M; Farid NA; Ikeda T
Drug Metab Pharmacokinet; 2008; 23(6):412-20. PubMed ID: 19122335
[TBL] [Abstract][Full Text] [Related]
11. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
Ramírez J; Innocenti F; Schuetz EG; Flockhart DA; Relling MV; Santucci R; Ratain MJ
Drug Metab Dispos; 2004 Sep; 32(9):930-6. PubMed ID: 15319333
[TBL] [Abstract][Full Text] [Related]
12. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
Richter T; Mürdter TE; Heinkele G; Pleiss J; Tatzel S; Schwab M; Eichelbaum M; Zanger UM
J Pharmacol Exp Ther; 2004 Jan; 308(1):189-97. PubMed ID: 14563790
[TBL] [Abstract][Full Text] [Related]
13. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel.
Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Kagami T; Iwaizumi M; Hamaya Y; Osawa S; Sugimoto K; Umemura K
J Thromb Thrombolysis; 2017 Apr; 43(3):333-342. PubMed ID: 27981489
[TBL] [Abstract][Full Text] [Related]
14. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
15. Clopidogrel, CYP2C19, and a Black Box.
Ford NF; Taubert D
J Clin Pharmacol; 2013 Mar; 53(3):241-8. PubMed ID: 23381692
[TBL] [Abstract][Full Text] [Related]
16. Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?
Kenngott S; Olze R; Kollmer M; Bottheim H; Laner A; Holinski-Feder E; Gross M
Eur J Med Res; 2010 May; 15(5):220-4. PubMed ID: 20562062
[TBL] [Abstract][Full Text] [Related]
17. Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.
Zahno A; Brecht K; Bodmer M; Bur D; Tsakiris DA; Krähenbühl S
Br J Pharmacol; 2010 Sep; 161(2):393-404. PubMed ID: 20735423
[TBL] [Abstract][Full Text] [Related]
18. CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel.
El-Halabi MM; Zgheib N; Mansour NM; Malli A; Ghaith OA; Mahfouz R; Alam S; Sharara AI
J Cardiovasc Pharmacol; 2013 Jul; 62(1):41-9. PubMed ID: 23474843
[TBL] [Abstract][Full Text] [Related]
19. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
Kita T; Sakaeda T; Baba T; Aoyama N; Kakumoto M; Kurimoto Y; Kawahara Y; Okamura N; Kirita S; Kasuga M; Okumura K
Biol Pharm Bull; 2003 Mar; 26(3):386-90. PubMed ID: 12612455
[TBL] [Abstract][Full Text] [Related]
20. Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling.
Johnson DA; Chilton R; Liker HR
Postgrad Med; 2014 May; 126(3):239-45. PubMed ID: 24918808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
